Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InhaleRx Limited ( (AU:NX1) ) just unveiled an announcement.
Nexalis Therapeutics reported net operating cash outflows of A$474,000 for the quarter ended 31 March 2026, driven primarily by A$350,000 in research and development spending alongside staff and corporate expenses, and recorded a further A$16,000 in investing cash outflows mainly for property, plant and equipment. These outflows were more than offset by A$565,000 of net cash from financing activities, including equity issuance and new borrowings, resulting in a net increase in cash of A$436,000 for the quarter and providing the company with additional liquidity to support ongoing development and operations.
The latest cash flow report underscores Nexalis Therapeutics’ dependence on external capital to fund its R&D-heavy operations, a pattern common among early-stage biotech firms with limited revenue. The strengthened cash position may reassure investors and creditors about the company’s near-term funding runway, but the continued negative operating cash flows highlight the importance of future capital access and eventual commercialisation for long-term sustainability.
More about InhaleRx Limited
Nexalis Therapeutics Limited is an ASX-listed biotechnology company focused on research and development activities, with associated product manufacturing, staff, and corporate costs typical of an early-stage life sciences business. The company does not yet appear to generate material customer receipts, indicating a pre-revenue or early-revenue stage focused on building its therapeutic pipeline.
Average Trading Volume: 164,123
Technical Sentiment Signal: Sell
Current Market Cap: A$5.82M
For a thorough assessment of NX1 stock, go to TipRanks’ Stock Analysis page.